Genenta Science S.p.A (GNTA) Other Non-Current Assets (2020 - 2025)
Genenta Science S.p.A (GNTA) posted Other Non-Current Assets of $2.2 million for Q4 2025, up 273.4% sequentially from $587299.2 in Q2 2025, and up 573.42% YoY from $325648.0 in Q4 2024.
Genenta Science S.p.A (GNTA) Other Non-Current Assets (2020 - 2025) Analysis & Trends
Genenta Science S.p.A has reported Other Non-Current Assets for 6 years, with the latest figure at $2.2 million in Q4 2025.
- Quarterly Other Non-Current Assets rose 573.42% year-over-year to $2.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $2.2 million (up 573.42% YoY) and the FY2025 annual result came in at $2.2 million, up 573.42% from the prior year.
- Other Non-Current Assets climbed to $2.2 million in Q4 2025 per GNTA's latest filing, from $587299.2 in the prior quarter.
- Over five years, Other Non-Current Assets peaked at $2.3 million in Q2 2023 and troughed at $3574.6 in Q2 2022.
- A 5-year average of $1.1 million and a median of $1.1 million in 2023 frame the typical range for Other Non-Current Assets.
- The sharpest annual moves came in 2023 and 2024: Other Non-Current Assets soared 63984.92% in 2023, then plunged 82.06% in 2024.
- Over 5 years, Other Non-Current Assets stood at $1.4 million in 2021, then advanced by 15.07% to $1.6 million in 2022, then tumbled by 33.85% to $1.1 million in 2023, then tumbled by 69.87% to $325648.0 in 2024, then soared by 573.42% to $2.2 million in 2025.
- According to Business Quant data, Other Non-Current Assets over the past three periods registered $2.2 million, $587299.2, and $325648.0 for Q4 2025, Q2 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 618.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 109.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 65.13 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 202.31 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 104.44 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 62.96 Mn |
| 10 | Genenta Science S.p.A | 25.03 Mn | -34.07 Mn | - | 2.19 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.19 Mn |
| Jun 30, 2025 | 587,299.17 |
| Dec 31, 2024 | 325,648.04 |
| Jun 30, 2024 | 411,015.68 |
| Dec 31, 2023 | 1.08 Mn |
| Jun 30, 2023 | 2.29 Mn |
| Dec 31, 2022 | 1.63 Mn |
| Jun 30, 2022 | 3,574.64 |
| Dec 31, 2021 | 1.42 Mn |
| Dec 31, 2020 | 1.13 Mn |